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Abstract: The present study was designed to evaluate the effects of flavonoids luteolin (L) and
quercetin + luteolin (Q + L) in combination with commonly used antibacterial agents against
methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates and S. aureus (ATCC 43300).
Minimum inhibitory concentrations (MICs) of L and Q + L, as well as the MICs of flavonoids
in combination with antibiotics were determined and results showed an increased activity of
flavonoids with antibiotics. The synergistic, additive, or antagonistic relationships between flavonoids
(L and Q + L) and antibiotics were also evaluated, and additive and synergistic effects were observed
for some antibiotic + flavonoid combinations. In addition, some combinations were also found to
damage the bacterial cytoplasmic membrane, as assessed through potassium leakage assay. The effects
of flavonoids and flavonoids + antibiotics on mecA gene mutations were also tested, and no functional
variation was detected in the coding region.
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1. Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) strains first became clinically relevant in 1968
when, in a Boston hospital, second-generation penicillin was ineffective as an antibiotic agent [1];
since then, reports on MRSA have been continuously rising. This issue is a global risk in developed
countries such as Japan and Korea, which have a frequency of MRSA from 0% to around 70%,
while increases of 40% in the UK and USA, and of 30% in Belgium, have been observed. However,
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this condition is not only confined to developed countries, and the situation is even worse in developing
countries such as Pakistan, where the prevalence of MRSA is rapidly increasing, especially in the
last decade. It has also been observed that MRSA incidence varies from region to region and even
in different hospitals within the same region. In 1999, less than 50% of S. aureus clinical isolates
from the intensive care unit in National Nosocomial Infection Surveillance system were found to be
MRSA strains; in the next five years, this peaked to 63%, with reports of co-resistance for antibiotics
such as Gentamycin, Ciprofloxacin, Rifampicin, Cotrimoxazole, Tetracycline, and Clindamycin [2].
A 10-month multicenter study revealed a 42% frequency of MRSA strains in S. aureus isolates, which is
very alarming [3].
Flavonoids have been found to be effective against Gram-positive bacteria [4]. In a study on
naringenin, apigenin, quercetin, kaempferol, and 7-O-butyl naringenin against S. aureus strains
isolated from meat, all the compounds exhibited bacteriostatic activity. Quercetin was found to
be the most effective, while electron microscopy analysis revealed bacterial cell wall damage by
7-O-butyl naringenin [5]. In another study, propolis obtained from two different sources was evaluated
against clinical isolates and standard MRSA strains. The antibacterial activity of propolis was attributed
to three flavonoids, in which pinobanksin-3-O-acetate and pinocembrin were reported to be effective
against MRSA [6]. Similarly, in a separate study, luteolin, quercetin, chlorogenic acid, apigenin,
and scutellarin were reported for their antibacterial activity against 29 MRSA clinical isolates [7].
Due to the rapidly growing resistance in S. aureus, this study was designed to evaluate the
anti-MRSA effects of luteolin and quercetin alone and in different combinations with conventional
antibiotics, in order to seek alternative therapeutic options to cope with antibiotic resistance and face
the threat posed by this bacterium.
2. Results and Discussion
Antibiotic resistance in S. aureus is a global phenomenon and is constantly increasing due to the
indiscriminate use of antibiotics, especially in developing countries such as Pakistan [8]. This has
hastened the search not only for new and effective therapeutic agents, but also for making already
blunted antibiotics effective again—the latter is a very handy option since new drug discovery requires
huge investments and, generally, a very long time. There are many reports on the activity of flavonoids
against S. aureus [8]. For instance, Halostachys caspica is known to contain seven different flavonoids
including luteolin, which were evaluated for their activity against different bacterial strains such as
Escherichia coli, Pseudomonas lachrymans, Xanthomonas vesicatoria, S. aureus, S. haemolyticus, and the
fungus Mangnaprothe oryzae. Luteolin was found to be effective against all the tested strains [9].
Similarly, in another study, luteolin showed activity against MRSA [10]. Virulence factors of S. aureus
represent an important aspect in pathogenesis, toxins in particular. Luteolin decreased α-toxin
production by S. aureus and exhibited activity against MRSA isolates [11], in agreement with previous
reports [12,13].
In another study on flavonoids, catechins, (−) epigallocatechin gallate (EGCG), and (−)
epicatechin gallate (ECG) were associated with a decrease of MICs when used in combination with
antibiotics [14]. A study exploring the mechanism of action of EGCG showed that interference in the
biosynthesis of bacterial cell wall by binding with the peptidoglycan layer was the probable cause of
bacterial inhibition. Moreover, ECG was found to generate lipoteichoic acids, thus causing changes in
the chemical structure of teichoic acid within the bacterial cell wall [15]. Consequently, β-lactams such
as ampicillin and amoxicillin more effectively damaged the bacterial cell wall. However, two other
non-galloylated catechins from green tea extract, i.e., epigallocatechin (EGC) and (−)-epicatechin
(EC), were not able to reduce bacterial resistance to β-lactams; they produced a synergistic effect
when used along with EGCG and ECG. Therefore, these non-galloylated catechins were suggested to
increase the galloylated catechin (EGCG and ECG) binding capacity to the bacterial cell membrane,
thus suggesting their probable combined action. Moreover, non-galloylated catechins also increased
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oxacillin sensitivity against MRSA [16]. These studies suggest the complex interactions between
flavonoids and bacterial cell.
Different concentrationsof luteolin were tested for their activity against MRSA, and 600 µg was
the effective concentration producing zone of inhibitions >10 mm (Figure 1), i.e., 10.8 ± 0.2 and
10.5 ± 0.2 mm against MRSA clinical isolates and ATCC 43300 strain, respectively.
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Figure 1. Average zone of inhibition (mm ± standard deviation) of luteolin against MRSA
(methicillin-resistant Staphylococcus aureus) ATCC 43300 strain and MRSA clinical isolates (n = 100).
In addition, luteolin increased the activity of conventional antibiotics. The highest enhancing effect
was observed for I P, and inhibitory zones were also recorded for other antibiotics like AMO, CEPH,
ME, a d CET. However, the activities of CIP and LEV were educed. T is is an interesting finding
and, currently, we are investigating the principal mechanism(s) involved, such as physicochemical
interaction between flavonoid and CIP or LEV, or other interactions with different molecular sites.
A comparison between the activities of antibiotics and luteolin + antibiotics against standard MRSA
strain and MRSA clinical isolates is shown in Figure 2.
Luteolin showed an antimicrobial enhancing effect on CET, higher than on AMP, ME, and CEPH;
however, it had no effect on AMO. In general, these ineffective antibiotics acquired activity against both
MRSA clinical is lates and the standard strain when combined with luteolin. The zones of inhibition
of AMP increased from inactivity (≤6 mm) t 11.3 ± 0.2 mm aga st ATCC 43300 in c mbination
with luteolin, while, against the clinical isolates, the inhibitory zones increa ed to 11.5 ± 0.2 mm.
In the case of inactive CEPH, combination with luteolin produced inhibitory zones of 13.3 ± 0.3 mm
and 13.7 ± 0.2 mm against ATCC 43300 strain and clinical isolates, respectively. The inhibition zones
for CET + L were 14.6 ± 0.3 mm and 15.3 ± 0.3 mm against standard strain and clinical isolates,
respectively. IMP was the only antibiotic active against MRSA, which showed a further increase in
activity with luteolin, as inhibition zones increased from 16.0 ± 0.9 to 18.0 ± 0.4 and from 16.1 ± 0.4 to
18.2 ± 0.4 mm against reference standard and clinical strains, respectively. The change in the activity of
antibiotics, in combination with luteolin, was found to be significant (p < 0.001). Similarly, the efficacy
of different concen rations of qu rcetin, alon and in combination wi h antibiotics, has bee previously
reported against the S. aureus ATCC 43300 strain and its clinical isolates [17].
The results from the preliminary screening were further quantified by MIC assays, in which
an effective concentration of 500 µg/mL luteolin was used. This concentration was in agreement
with an earlier report [10], in which 38 flavonoids including 500 µg/mL luteolin were tested
for their activities against MRSA, vancomycin-resistant Enterococci (VRE), Klebsiella pneumoniae,
and Staphylococcus epidermidis. However, only luteolin was found to inhibit MRSA. Luteolin was
also studied for its synergistic activity with AMO and was found to significantly reduce the viability of
bacteria compared to luteolin and AMO alone [18]. In this context, luteolin was used in combination
with querc tin as well as conventionally used antibiotics.
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The combination L + Q was tested for activity against MRSA clinical isolates and S. aureus ATCC
43300 strain. This combination showed a higher efficacy than the individual compounds (Figure 3).Int. J. Mol. Sci. 2016, 17, 1947 4 of 16 
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Figure 2. Average zone of inhibition (mm ± standard deviation) of luteolin (L) in combination
with antibiotics against * MRSA clinical isolates (n =100); † MRSA ATCC 43300 strain.
AMO = amoxicillin; AMP = ampicillin; CEPH = cephradine; CET = ceftriaxone; IMP = imipenem;
ME = methicillin; VAN = vancomycin; LEV = levolfloxacin; CIP = ciprofloxacin; ERY = erythromycin;
S-T = sulfamethoxazole-trimethoprim; CEF = cefixime.
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Figure 3. Average zone of inhibition (mm ± standard deviation) of luteolin + quercetin against MRSA
(methicillin-resistant Staphylococcus aureus) ATCC 43300 strain and MRSA clinical isolates (n = 100).
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The zones of inhibition observed with L + Q were 15.0 ± 0.2 mm against ATCC 43300 strain and
15.2± 0.2 mm in case of clinical isolates. Antibiotics improved their anti-MRSA activity when combined
with L + Q, as reflected in the significant increase (p < 0.01) in inhibition zones compared to their
individual inhibitions (Figure 4). The highest increase in activity was for CET with L + Q combination
for MRSA ATCC 43300 strain (22.5 ± 0.2 mm), as well as MRSA clinical isolates (22.7 ± 0.6 mm);
notably, this antibiotic was previously inactive. Pure ethanol was used to prepare stock solutions of L
(15 g/L) and Q (10 g/L), which were then used in disk diffusion assays and in broth macrodilution MIC
assays. In both assays, ethanol had no impact on the growth of bacteria (standard ATCC 43300 strain
and clinical isolates), probably due to the evaporation of ethanol in a disk diffusion assay following
the application of a test concentration on sterile blank disks, and due to dilution in MIC assays.
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(n = 100) and † MRSA ATCC 43300 strain. (p < 0.05 for IMP; p < 0.001 ME, CET, CEPH, AMP, AMO).
Similarly, activity increased for AMP (20.0 ± 0.64 and 20.1 ± 0.6 mm), CEPH (20.5 ± 0.6 and
20.7 ± 0.7 mm), and ME (19.0 ± 0.6 and 19.4 ± 0.6 mm) against MRSA (ATCC 43300 strain and clinical
isolates, respectively). Q + L in combination enhanced IMP activity, from 16.0 ± 0.9 and 16.1 ± 0.9 to
24.5 ± 0.25 and 24.72 ± 0.29 mm against ATCC 43300 strain and clinical isolates, respectively. The IMP
inhibition zones were greater than the CET ones, though, interestingly, the overall increase in activity
of CET was higher than that of IMP, as the former rose from inactivity to 22.5± 0.2 mm, while the latter
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increased from 16.0 ± 0.9 to 24.5 ± 0.2 mm against ATCC 43300 strain. L + Q had no effect on AMO
and SULPH-TRI, while the combination showed negative effect on CIP and LEV activities (Figure 4).
The MIC of luteolin was 500 µg/mL against ATCC 43300 strain and 39 clinical isolates, whereas it
was 1000 µg/mL against the remaining isolates (n = 61). The exact MIC of L by incremental
increase approach against clinical isolates (n = 61) was in the range of 500–540 µg/mL and averaged
516.83 ± 15.67 µg/mL against the clinical isolates, while for ATCC 43300 strain it was 500 µg/mL
(Table 1).
Table 1. MIC of luteolin by serial half-dilution and incremental increase method against
methicillin-resistant Staphylococcus aureus (MRSA) strains.
Method
MRSA ATCC 43300 Strain MIC
(µg/mL)
MRSA Clinical Isolates MIC
(µg/mL)
Serial half dilution 500
500 (n = 39)
1000 (n = 61)
Incremental increase approach 500 516.83 ± 15.67
a
MIC range: 500–540
a Mean ± standard deviation.
The MIC of L was further reduced in combination with antibiotics, thereby exhibiting an increase
in its activity (Figure 5). The highest decrease in MIC of L was observed with IMP for ATCC 43300
strain and clinical isolates, compared to other test antibiotics. The MIC of L alone was 500 µg/mL
against ATCC 43300 strain, which decreased to 400 µg/mL when combined with IMP; similarly,
against clinical isolates, MIC of L improved from 516.83 ± 15.67 to 417 ± 14.95 µg/mL.
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A comparison between the MICs of L alone (Table 1) and in combination with antibiotics against
ATCC 43300 strain and clinical isolates (Figure 5) indicated that the MIC reduction of L was nearly
the same in its combination with AMP and CEPH, as the MIC of L improved from 500 to 440 µg/mL
against ATCC 43300; conversely, MIC reduction was higher when rutin was combined with IMP and
CET. The MIC of L with CET decreased to 420 and 437.20 ± 15.56 µg/mL against standard strain and
clinical isolates, respectively (p < 0.001).
The MIC of L was 400 µg/mL when combined with Q against the standard strain (Table 2).
Similarly, in the case of 42 clinical isolates, the MIC of L in combination with Q was 400 µg/mL,
whereas, against the remaining 58 clinical isolates, it was 800 µg/mL. The same trend was observed
for Q, as its MIC decreased from 300 to 200 µg/mL against ATCC 43300 strain, while, against clinical
isolates, MIC was 200 µg/mL (n = 42) and was 400 µg/mL (n = 58).
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Table 2. MICs of luteolin + quercetin (L + Q) by serial half-dilution method and incremental increase
approach against methicillin-resistant Staphylococcus aureus (MRSA strains).
Method
MRSA ATCC 43300 Strain MIC
(µg/mL)
MRSA Clinical Isolates MIC
(µg/mL)
Serial half dilution 400 + 200
400 + 200 (n = 42)
800 + 400 (n = 58)
Incremental increase approach 380 + 200
(394.06 ± 13.75 a) + (215.04 ± 12.72)
MIC range: L = 380–420
Q = 200–240
a Mean ± standard deviation.
The MIC of L + Q was also measured through the incremental increase approach to define the
inhibitory concentrations of flavonoid combination against ATCC 43300 strain and the clinical isolates.
The results (Table 2) showed that the MIC of L and Q in combination against ATCC 43300 were
380 and 200 µg/mL, respectively. The average MIC of L in combination with Q against 100 clinical
isolates was 394.06 ± 13.75 µg/mL, while the MIC of Q was 215.04 ± 12.72 µg/mL. From the results
in Table 2, the MIC of L in combination with Q decreased from 500 to 380 µg/mL against ATCC
43300, while, against clinical isolates, the average MIC was 394.06 ± 13.75 µg/mL, lower than the
average MIC (516.83 ± 15.67 µg/mL) when L was used alone. Similarly, the MIC of Q improved to
200 µg/mL for ATCC 43300 and, in the case of clinical samples, the average MIC decreased from
279.00± 14.65 to 215.04± 12.72 µg/mL, which is suggestive of some synergism or additive relationship
between flavonoids.
From the results reported in Table 3, it may be concluded that, in Q + L combination, the MIC of
both flavonoids improved further when they were combined with antibiotics in comparison to Q + L
alone, which is indicative of their increased activity against MRSA. For instance, the average MIC
of L in Q + L combination with AMP decreased from 500 to 380 µg/mL, while the MIC of Q in this
combination decreased from 260 to 200 µg/mL for the ATCC 43300 strain. A similar trend of reduction
(p < 0.01) was observed in the MICs of flavonoids when used with other antibiotics. The MIC reduction
of antibiotics with flavonoids was in the following order: Antibiotics + Q + L > Antibiotics + Q >
Antibiotics + L.
Table 3. Exact MICs by incremental approach of quercetin + luteolin (Q + L) in combination with
antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains.
Antibiotics Q + L with Antibiotic MIC (µg/mL)
AMO (amoxicillin) † 200 + 380
AMO * 214.06 ± 13.72 a + 394.06 ± 13.75 ***
MIC * RANGE
Q = 200–240
L = 380–420
AMP (ampicillin) † 120 + 280
AMP * 134.06 ± 13.85 + 294.06 ± 13.75 ***
MIC * RANGE
Q = 120–160
L = 280–320
CEPH (cephradine) † 100 + 260
CEPH * 116.06 ± 15.80 + 278.06 ± 15.61 ***
MIC* RANGE
Q = 100–140
L = 260–300
CET(ceftriaxone) † 80 + 240
CET * 94.06 ± 15.43 + 254.06 ± 14.21 ***
MIC * RANGE
Q = 80−120
L = 240−300
IMP (imipenem) † 80 + 260
IMP * 97.40 ± 14.49 + 274.06 ± 14.02 ***
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Table 3. Cont.
Antibiotics Q + L with Antibiotic MIC (µg/mL)
MIC * RANGE
Q = 80−120
L = 260−300
ME(methicillin) † 120 + 300
ME * 134.12 ± 14.95 + 314.06 ± 14.21 ***
MIC * RANGE
Q = 120−160
L = 300−340
† S. aureus ATCC 43300 strain; * Clinical isolates (n = 100); a Mean ± standard deviation; *** p < 0.001 compared
to flavonoids alone.
In combination with flavonoids, all antibiotics facing resistance exhibited activity against MRSA,
especially the cell wall synthesis inhibitors.
As shown in Figure 6, the MIC against ATCC 43300 strain decreased from 128 µg/mL, for AMP,
to 64 µg/mL in AMP + L, whereas, against clinical isolates, the average MIC dropped from
162.85 ± 68.05 µg/mL, for AMP, to 81.43 ± 34.02 µg/mL in AMP + L. In combination with Q + L,
the MIC of AMP decreased to 16 µg/mL for ATCC 43300 and its average MIC with Q + L decreased to
12.56 ± 3.98 µg/mL for the clinical isolates. The MIC of CEPH was 256 µg/mL against ATCC 43300
and average MIC was 200.96 ± 63.69 µg/mL for clinical isolates, while the average MIC of CEPH
with Q + L was 50.38 ± 17.92 µg/mL for the clinical isolates. The reduction in the MIC of CEPH with
Q + L (16 µg/mL) was higher than that of L (128 µg/mL) against ATCC 43300 strain. The MIC of
CET was 64 µg/mL for ATCC 43300, but, in combination with Q, L and Q + L, the MICs dropped
to 8, 32, and 4 µg/mL, respectively. The MIC of IMP + L against ATCC 43300 was 16 µg/mL, while,
against the clinical isolates, the average MIC decreased to 80.16 ± 42.03 µg/mL. The MIC of IMP
with Q + L against ATCC 43300 was 4 µg/mL, half that with L. Therefore, the reduction caused by
Q + L in the MIC of IMP was higher than the reduction by L. The results revealed that the MICs of
IMP decreased to a much higher extent when combined with flavonoids (p < 0.001). The reason for
determining the MICs of these antibiotics alone and in combination with flavonoids was to ascertain
whether synergistic or additive relationships exist between them.
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It has been previously reported that catechins transform resistance of β-lactams in S. aureus
by changing the cell membrane biophysical properties and affecting the movement of molecules
across the cell membrane, as they compromise the functions of proteins embedded in the bilayer [19].
Synergism between amoxicillin and luteolin was previously reported against amoxicillin-resistant
E. coli. The results revealed that amoxicillin and luteolin, in combination, decreased the number
of amoxicillin-resistant E. coli cells and altered the permeability of the bacterial cell membrane [18].
Therefore, this study was designed to evaluate the potential of luteolin in combination with quercetin
and other conventional antibiotics, especially cell wall inhibitors, against MRSA.
To establish whether a synergistic, additive, or antagonistic relationship existed between
flavonoids and antibiotics, FICIs were determined. Data from Table 4 indicate a synergistic interaction
between Q + L + CET and Q + L + IMP, while an additive relationship was found for the rest of
the combinations.
Table 4. Fractional inhibitory concentration indices (FICI) of flavonoids quercetin (Q), luteolin (L),
and antibiotics against MRSA strains.
Flavonoids + Antibiotics
FICI
MRSA ATCC 43300 MRSA Clinical Isolates (n = 100) Inference
L + AMP (ampicillin) 0.9 1 Additive
L + CEPH (cephradine) 0.8 1 Additive
L + CET (ceftriaxone) 0.85 1 Additive
L + IMP (imipenem) 0.82 0.9 Additive
L + ME (methicillin) 0.9 1 Additive
Q + L + AMP 0.65 0.68 Additive
Q + L + CEPH 0.60 0.65 Additive
Q + L + CET 0.45 0.50 Synergistic
Q + L + IMP 0.45 0.49 Synergistic
Q + L + ME 0.65 0.69 Additive
In our previous study, an additive effect [13] was observed for quercetin in combination with
antibiotics, with FICI <1. In the present report, additive effect is also found for Q + L with AMP,
CEPH and MET (FICI ≤ 1). Interestingly, combination Q + L has a synergistic effect with IMP and CET
(FICIs ≤ 0.5). Our findings are in agreement with previous reports [20,21] showing either additive or
synergistic relationships between flavonoids and antibiotics.
The damage to the cytoplasm membrane was assessed by potassium leakage for all bacteria
(ATCC 43300 strain and clinical isolates) in the case of L, Q [16] and Q + L (p < 0.05) (Figure 7).
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Figure 7. Potassium (K+) loss (ppm) caused by Quercetin (Q), luteolin (L) and quercetin + luteolin
(Q + L), against MRSA ATCC 43300 strain and MRSA clinical isolates; results are expressed as
mean ± standard deviation (p < 0.001). Results for Q alone have been previously reported [13].
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Cytoplasmic membrane damage was observed for nearly all the antibiotics in combination with
flavonoids (Figure 8). In our previous report [16], K+ loss in case of AMO was 25.7 ppm for ATCC
43300 strain, while for the clinical isolates the average K+ loss was 25.79 ± 0.16 ppm. The highest
leakage (26.6 ppm) of potassium was observed for IMP against ATCC 43300, while for clinical isolates
it was 26.79 ± 0.14. The K+ leakage was higher in the case of Q for ATCC 43300 strain (28.4 ppm)
and clinical isolates (28.49 ± 0.14 ppm) compared to L, for which the K+ leakage for ATCC 43300 and
clinical isolates were 25.4 and 25.49 ± 0.15 ppm, respectively. However, when Q and L were combined,
the damage became more pronounced with a leakage of 30.5 and 30.53 ± 0.16 ppm against ATCC
43300 and clinical isolates, respectively, which were higher than the potassium losses caused by Q and
L individually. Therefore, antibiotics + flavonoids combination caused a significant potassium loss
compared to flavonoids and antibiotics when used alone (p < 0.01).
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Figure 8. Potassium (K+) loss (ppm) caused by luteolin and luteolin + quercetin (L + Q) in combination
with antibiotics against * MRSA (methicillin-resistant Staphylococcus aureus) clinical isolates (n = 100)
and † MRSA ATCC 43300strain; results are expressed as mean ± standard deviation (p < 0.01 for all
combinations apart from AMO).
Antimicrobial compounds whose mechanism of action involves microbial cell wall and membrane
damage, e.g., phenolic compounds, penicillin, etc., represent a major group. As a consequence,
intracellular constituents like proteins and inorganic ions leak from the cells, thus causing irreparable
cell damage [22]. Flavonoids have been shown to inflict such damage, such as galangin, which causes
significant potassium loss compared to the control and alters cytoplasmic membrane permeability [23].
Similar results were obtained with leucasin, another flavonoid, on S. aureus [24].
On the basis of these reports, cell wall damage by flavonoids, antibiotics, and flavonoids + antibiotics
was evaluated using the potassium loss assay through flame photometry. To the best of our knowledge,
no study has been carried out to evaluate L, L + Q, and their combined effects with conventional
antibiotics on cell membra e damage. Our findings s ggest that L, L + Q, and their combinations
with antibiotic induce cyt plasmic membrane damage, as indicated by the loss of intracellular K+,
which ultim tely compromises the integrity and viability of bacterial cells. As previously mentioned,
the ant biotics used i the present study w re cell wall inhibitors with a kno n mec anism of action.
The release of K+ provides strong evidence that these flavonoids, antibiotics, and t eir combinations
are responsible for damage to the bacterial cell wall, thus explaining their antibacterial activity
against MRSA.
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In the case of the mecA gene sequence comparison in treated and untreated MRSA, after alignment,
no mutation was observed. As sequencing of the mecA gene in MRSA did not reveal any
polymorphism/mutation in the coding region of the gene, there could be a possibility of mutations
in the regulatory regions of mecA, which results in gene down regulation or non-expression.
The mechanism of action of flavonoids, in combination with antibiotics, in the cell wall synthesis
inhibition may be due to their effects on different targets.
The size of the mecA gene reported was in accordance with the study where a 533-bp mecA DNA
fragment was amplified in 100% MRSA clinical isolates. This study was carried out to detect the
presence of mecA in 273 S. aureus clinical isolates by PCR [25]. Similarly, in another study, the amplified
mecA gene product was also 533 bp, used for the identification of MRSA from 94 S. aureus clinical
isolates collected from both humans and animals in Bangladeshi medical hospitals and veterinary
clinics. Basically, the mecA gene is present in the methicillin-resistant Staphylococcus aureus. This gene
within MRSA encodes a specific penicillin-binding protein known as PBP-2a, responsible for antibiotic
resistance in S. aureus. This is a β-lactam resistant PBP that possesses low affinity for binding with
β-lactams [26]. Though the significance of PBP 2 is well documented, its role in cell wall biosynthesis
and drug resistance has not yet been defined. The survival and development of S. aureus are dependent
on both PBP-2 and its transpeptidase portion. The penicillin-binding protein in MRSA is PBP 2a,
which is a protein encoded by the mecA gene. This PBP 2a acts as a transpeptidase, which is essential
for the growth of this bacterium [27–29].
Sato and colleagues [30] observed the synergism between β-lactam antibiotics (methicillin,
oxacillin, cephaperin, panipenem, streptomycin, ofloxacin, levolfloxacin, vencomycin, erythromycin,
kanamycin, and fosfomycin) and flavonoids (flavones and its derivatives), resulting in an increase in
the susceptibility of these antibiotics to MRSA. These authors detected a significant reduction in the
MIC of the antibiotics investigated. The possible mechanism for this improvement of antibiotic activity
by flavonoids may be due to the fact that PBP-2a plays a pivotal role in the cell wall biosynthesis in
MRSA [31]. Notably, PBP-2a acts as a bridge in the cross linking of N-acetylmuramyl-pentapeptide with
pentaglycine, which are two important components of the cell wall. As a result of the synergistic effect
of flavonoids and antibiotics, the peptidoglycan synthesis is probably inhibited, which, in turn, reduces
the concentration of N-acetylmuramyl-pentapeptide or pentaglycine in the developing cell wall.
Therefore, PBP-2a would be unable to cross-link the peptidoglycans, thus causing the improvement of
antibiotic MIC induced by flavonoids against MRSA. From the present study, it seems that flavonoids
may affect the integrity of the bacterial cell wall, as indicated by the loss of potassium ions. The resultant
overall cell wall biosynthesis inhibition by flavonoids combined with antibiotics could be the main
reason for the enhanced activity of antibiotics.
Another possible mechanism for the synergistic or additive relationship of flavonoids and
antibiotics can be the suppression of the efflux pump in MRSA. Kosmidis et al. [32] have identified
the existence of eight efflux pumps in MRSA, namely norA, norB, norC, mdeA, qacA/B, mepA, smr, sepA,
and abcA [33]. It has been demonstrated that the main expressed efflux genes included norA, norB,
norC, mdeA, and mepA [34], while the resistance to β-lactamantibiotics is due to abcA efflux pump.
Gibbons et al. showed that the norA efflux pump is inhibited by epicatechin gallate (ECG) [35].
It has been observed that monomers (+)-catechin, (−)-ECG, and (−)-epigallocatechin (EGC),
in combination with oxacillin, intensify the antibiotic activity against MRSA [36]. The combined effect
of these flavonoids was found to be higher than their individual effects. An in vivo study in mice
revealed that a combination of (+)-catechin with (−)-ECG greatly reduced the load of bacteria in mice.
The effect on bacterial efflux pumps was determined by measuring the daunorubicin (a β-lactam)
accumulated in MRSA bacteria found in the infected mice. In addition, the mRNA expression analysis
showed a down regulation of the efflux pumps in MRSA. To summarize, (+)-catechin and (−)-ECG
increased the activity of β-lactam antibiotics (oxacillin and daunorubicin) against MRSA by down
regulating the gene expression of efflux pumps and thus increasing the amount of antibiotics in
bacterial cells.
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3. Experimental Section
3.1. Materials
The antibiotic discs were from Oxoid (Hampshire, UK) and included amoxicillin (AMO; 25 µg),
ampicillin (AMP; 10 µg), ceftriaxone (CET; 30 µg), cefixime (CEF; 5 µg), cephradine (CEPH; 30 µg),
erythromycin (ERY; 15 µg), vancomycin (VAN; 30 µg), methicillin (ME; 10 µg), ciprofloxacin (CIP; 5 µg),
levolfloxacin (LEV; 5 µg), sulfamethoxazole-trimethoprim (S-T; 25 µg), and imipenem (IMP; 10 µg).
The blank discs were purchased from Himedia (Mumbai, India). Flavonoids luteolin (L) and quercetin
(Q), were purchased from Sigma-Aldrich (Irvine, UK), as well as the ethanol used to prepare stock
solutions of luteolin (15 g/L) and quercetin (10 g/L). Nutrient agar (NA; CM0003B), Muller Hinton
agar (MHA; CM0337B), nutrient broth (NB; CM0001B), and Muller Hinton broth (MHB; CM0405B)
were from Oxoid, while mannitol salt agar (MSA; LAB007) was from Lab M Limited (Lancashire, UK).
3.2. Bacterial Culturing and Antibacterial Assays
Clinical isolates (n = 300) were obtained from the clinical microbiology laboratories of three
major tertiary care hospitals of Peshawar, KPK, Pakistan, Hayatabad Medical complex, Lady Reading
Hospital, and Khyber Teaching Hospital. The reference strain S. aureus (ATCC 43300, Rockville, MD,
USA) present in PCSIR laboratories was used as the positive control. All the clinical isolates were
sub-cultured on sterile MSA plates at the Department of Microbiology of PCSIR laboratories, Peshawar,
Pakistan. Following incubation at 37 ± 1 ◦C for 18–20 h, plates showing growth were selected
and subjected to routine microbiological tests like gram staining, catalase, and coagulase tests [37].
After basic characterization, isolated S. aureus were transferred to NB and incubated overnight at 37 ◦C.
Thereafter, the turbidity of bacterial growth was adjusted to 0.5 McFarland using sterile normal saline
(0.9% w/v NaCl in water solution). The standardized inoculum was used to make bacterial lawns
on sterile MHA plates subjected to methicillin discs. After overnight incubation at 37 ± 1 ◦C, plates
lacking zones of inhibition around methicillin discs or having <10 mm diameter zones were considered
to be methicillin-resistant S. aureus (MRSA).
To determine the response of MRSA clinical isolates and ATCC 43300 against luteolin,
luteolin + quercetin, antibiotics, and antibiotic + flavonoid combinations, disc diffusion assay was
used [38]. Luteolin (L) was tested alone, in combination with quercetin (L + Q) as well as with selected
antibiotics (Table 5) at different concentrations. The inhibitory zones were recorded after overnight
incubation at 37 ◦C and all compounds were considered to be active if the inhibitory zones were
>10 mm in diameter.
Table 5. Flavonoid concentrations used in antibiotic sensitivity assays.
Flavonoids Concentrations Used (µg)
Quercetin 100, 200, 300
Luteolin 100, 200, 300, 400, 500
3.3. Minimum Inhibitory Concentration (MIC) Assay
A broth macro-dilution method was used for MIC determination of L, L + Q, antibiotics,
and antibiotics + flavonoids, at different concentrations (Table 6). Antibiotics showing increased
activity in combination with flavonoids included amoxicillin, ampicillin, ceftriaxone, cephradine,
imipenem, and methicillin.
An incremental increase approach was adopted to determine the exact MICs of L, L + Q
alone, and in combination with antibiotics. In this approach, 20 µg increments were added to the
corresponding lower concentrations. Similarly, the MICs of antibiotics alone and in combination with
flavonoids against MRSA were also determined to confirm the synergistic or additive effects.
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Table 6. Concentrations of flavonoids and their combinations for MIC (minimum inhibitory
concentration) assays.
Flavonoids
Concentration Ranges Used for MIC Assays (µg/mL)
Broth Half Dilution Assay Incremental Assay (Exact MIC) †
Maximum Minimum Maximum Minimum
Luteolin 1000 125 600 460
Quercetin + Luteolin 400 + 800 100 + 200 320 + 500 180 + 360
† To determine the exact MIC of compounds, an incremental approach was adopted with 20 µg decrease in
each dilution.
The bacterial cultures were prepared as reported previously and compounds were transferred
into sterile tubes. The test tubes containing inoculums and compounds were incubated overnight at
37 ◦C. The MIC of the compounds was indicated by the absence of any visible growth in test tubes
after overnight incubation.
3.4. Fractional Inhibitory Concentration (FIC) and FIC Index
To determine the synergistic, antagonistic, or additive effects of flavonoids and antibiotics,
FICs were determined using previously described formulas [39]:
FIC of antibiotic (FICantibiotic) = MIC of antibiotic in combination/MIC of antibiotic alone;
FIC of flavonoid (FICflavonoid) = MIC of flavonoid in combination/MIC of flavonoid alone;
FIC Index (FICI) = FICantibiotic + FICflavonoid.
In case of a combination of two or more flavonoids, FIC were determined using the formula [34]:
FIC = (A/Ma) + (B/Mb)
where A and B are the MICs of compounds in combination, while Ma and Mb were individual MICs of
test compounds. The effect of drugs in combination were considered to be synergistic (≤0.5), additive
(>0.5 to 1), indifferent (>1 to <2), or antagonistic (≥2) based on previously established criteria [40].
3.5. Detection of Cytoplasmic Membrane Damage
The cytoplasmic membrane damage caused by flavonoids and their combinations with antibiotics
was determined using a flame photometer (PFP7, Jenway, Gothenberg, Sweden) at a wavelength of
766.480 nm. Instrument calibration and test procedure were in accordance with previously reported
method [16].
3.6. Modified Ames’s Test
3.6.1. Treatment of Bacterial Cultures with Flavonoids, Antibiotics, and Flavonoids + Antibiotics
MRSA (ATCC 43300) was inoculated aseptically in a nutrient broth and incubated overnight at
37 ◦C. Thereafter, flavonoids, antibiotics, and their combinations were mixed with 1 mL of overnight
grown culture at concentrations lower than their MICs and incubated at 37 ◦C for 30 min [41]. Genomic
DNA from treated cultures was extracted using a bacterial DNA extraction kit (Vivantis Technologies
Sdn, Selangor, Malaysia) as per the manufacturer’s instructions. Then, the mecA gene was amplified
using the extracted DNA as a template for PCR. The following oligonucleotides were used as
primers for amplification: Forward Primer (5’AAAATCGATGGTAAAGGTTGGC); Reverse Primer
(5’AGTTCTGCAGTACCGGATTTGC). Amplicons from MRSA ATCC 43300 strain treated with
flavonoids, flavonoids + antibiotics, and untreated were sequenced using an ABI 3300 (Thermo
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Fisher Scientific, Waltham, MA, USA) automated sequencer. A consensus sequence of 532 base pairs
(mecA gene) was obtained by aligning sequences obtained in FASTA, on the basis of forward and
reverse primers. The mecA gene sequences obtained from untreated cultures were aligned with those
from the treated ones, using BioEdit v.7.2.5 (Ibis Biosciences, an Abbott company, Carlsbad, CA, USA).
3.6.2. Statistical Analysis
Results of experiments are expressed as mean ± standard deviation (SD). The data were
analyzed by Student’s t-test using Statistical Package for Social Sciences (SPSS) version 19, IBM
Inc. (Armonk, New York, NY, USA); p < 0.05 was considered statistically significant.
4. Conclusions
Luteolin exhibited activity against both MRSA ATCC 43300 strain and clinical isolates, and its
antibacterial activity was further enhanced when it was used in combination with quercetin.
Furthermore, it was observed that luteolin, quercetin, and antibiotics have complemented each another
against MRSA. In particular, FICI results indicated additive and synergistic relationships between
these flavonoids and some antibiotics, especially the cell wall biosynthesis inhibitors. Potassium loss
analysis suggested damage to the cytoplasmic membrane and cell wall. Since no functional variation
was detected in the coding sequence of the mecA gene, a variation in the regulatory sequence of this
gene can be hypothesized, with resultant down regulation or non-expression. The susceptibility of
the MRSA bacteria might be due to changes in some other gene sequences putatively involved in the
mechanism of multi-drug resistance.
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